» Articles » PMID: 11447072

Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients with Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy

Overview
Journal Circulation
Date 2001 Jul 12
PMID 11447072
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Left ventricular hypertrophy (LVH), the clinical hallmark of familial hypertrophic cardiomyopathy (FHCM), is absent in a significant number of subjects with causal mutations. In transgenic rabbits that fully recapitulate the FHCM phenotype, reduced myocardial tissue Doppler (TD) velocities accurately identified the mutant rabbits, even in the absence of LVH. We tested whether humans with FHCM also consistently showed reduced myocardial TD velocities, irrespective of LVH.

Methods And Results: We performed 2D and Doppler echocardiography and TD imaging in 30 subjects with FHCM, 13 subjects who were positive for various mutations but did not have LVH, and 30 age- and sex-matched controls (all adults; 77% women). LV wall thickness and mass were significantly greater in FHCM subjects (P<0.01 versus those without LVH and controls). There were no significant differences in 2D echocardiographic, mitral, and pulmonary venous flow indices between mutation-positives without LVH and controls. In contrast, systolic and early diastolic TD velocities were significantly lower in both mutation-positives without LVH and in FHCM patients than in controls (P<0.001). Reduced TD velocities had a sensitivity of 100% and a specificity of 93% for identifying mutation-positives without LVH.

Conclusions: Myocardial contraction and relaxation velocities, detected by TD imaging, are reduced in FHCM, including in those without LVH. Before and independently of LVH, TD imaging is an accurate and sensitive method for identifying subjects who are positive for FHCM mutations.

Citing Articles

Clinical and Genetic Heterogeneity of HCM: The Possible Role of a Deletion Involving and .

Mancuso G, Marsan M, Neroni P, Soddu C, Lai F, Serventi L Genes (Basel). 2025; 16(2).

PMID: 40004541 PMC: 11855101. DOI: 10.3390/genes16020212.


Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.

Llamas-Esperon G, Berrios-Barcenas E, Cossio-Aranda J, Guerra-Lopez A, Magana-Serrano J, Iturralde-Torres P Arch Cardiol Mex. 2025; 94(Supl 4):1-75.

PMID: 39928711 PMC: 11824882. DOI: 10.24875/ACM.M25000098.


Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities.

Sequeira V, Waddingham M, Tsuchimochi H, Maack C, Pearson J J Mol Cell Cardiol Plus. 2025; 4():100036.

PMID: 39801694 PMC: 11708264. DOI: 10.1016/j.jmccpl.2023.100036.


Effects of genetic mutations on left ventricular myocardial mechanics and fibrosis patterns in hypertrophic cardiomyopathy.

Kim M, Kim Y, Chung H, Seo J, Park C, Kim T Sci Rep. 2025; 15(1):799.

PMID: 39755839 PMC: 11700167. DOI: 10.1038/s41598-025-85201-0.


Radiographic and echocardiographic evaluation in rescued Korean raccoon dogs ().

Park J, Kim M, Han J, Lee K, Yoon H Front Vet Sci. 2024; 11:1361843.

PMID: 39005719 PMC: 11239572. DOI: 10.3389/fvets.2024.1361843.


References
1.
Marian A, Wu Y, Lim D, McCluggage M, Youker K, Yu Q . A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 1999; 104(12):1683-92. PMC: 409884. DOI: 10.1172/JCI7956. View

2.
Marian A . Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000; 355(9197):58-60. DOI: 10.1016/s0140-6736(99)06187-5. View

3.
Nagueh S, Kopelen H, Lim D, Zoghbi W, Quinones M, Roberts R . Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2000; 102(12):1346-50. PMC: 2907266. DOI: 10.1161/01.cir.102.12.1346. View

4.
Lim D, Lutucuta S, Bachireddy P, Youker K, Evans A, ENTMAN M . Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001; 103(6):789-91. PMC: 2779524. DOI: 10.1161/01.cir.103.6.789. View

5.
Marian A, Roberts R . The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001; 33(4):655-70. PMC: 2901497. DOI: 10.1006/jmcc.2001.1340. View